Cayman Mocetinostat

Mocetinostat is an orally available inhibitor of histone deacetylases (HDACs) that selectively targets HDAC1 and 2 (IC₅₀s = 0.15 and 0.29 µM, respectively), less potently inhibits HDAC3 and 11 (IC₅₀s = 1.66 and 0.59 µM, respectively) and has negligible actions against HDAC4-8.^1,2 It induces hyperacetylation of histones, causes cell cycle blockade, and induces apoptosis in cancer cells in vitro.^1,3 Mocetinostat also has antitumor activity in vivo, blocking the growth of human tumor xenografts in mice.¹ It also significantly reduces cardiac fibrosis following ischemic heart failure in mice.⁴

WARNING This product is not for human or veterinary use.